Literature DB >> 20597130

Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas.

Paolo A Zucali1, Iacopo Petrini, Elena Lorenzi, Maria Merino, Liang Cao, Luca Di Tommaso, Hye Seung Lee, Matteo Incarbone, Beatriz A Walter, Matteo Simonelli, Massimo Roncalli, Armando Santoro, Giuseppe Giaccone.   

Abstract

BACKGROUND: Thymic malignancies are rare tumors. The insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) system is involved in the development of the thymus. IGF-1R expression in thymic epithelial malignancies is unknown.
METHODS: The authors investigated the expression of IGF-1R and phosphorylated AKT serine 473 (p-AKT) by using immunohistochemistry and examined the clinicopathologic correlations in a retrospective, single-institution surgical series of 132 patients with thymic epithelial malignancies.
RESULTS: Earlier disease stage, less aggressive histologic types, and complete resection were significant positive prognostic factors for disease-related survival and progression-free survival, and being a woman was a better prognostic factor for disease-related survival. IGF-1R and p-AKT protein levels were expressed in 20% and 36% of thymic tumors, respectively. Both markers were expressed more commonly in recurrent disease than in primary tumors, in more aggressive subtypes, and in more advanced disease stages. There was a trend toward better survival and progression-free survival in patients who were negative for IGF-1R or p-AKT expression in the whole series. When only the 91 primary tumors, IGF1R expression was associated with worse progression-free survival (P < .001).
CONCLUSIONS: The current retrospective analysis demonstrated that disease stage, tumor histology, sex, and resection type were major prognostic factors in the survival of patients with thymic malignancies. The expression levels of IGF-1R and p-AKT in thymic tumors suggested that IGF-1R is a potential target for treatment.
© 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20597130      PMCID: PMC3057766          DOI: 10.1002/cncr.25367

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  38 in total

1.  Thymic carcinoma: a report of 13 cases.

Authors:  M Lucchi; A Mussi; M Ambrogi; A Gunfiotti; G Fontanini; F Basolo; C A Angeletti
Journal:  Eur J Surg Oncol       Date:  2001-11       Impact factor: 4.424

2.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

Authors:  Arnab Chakravarti; Jay S Loeffler; Nicholas J Dyson
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

Review 3.  The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.

Authors:  H M Khandwala; I E McCutcheon; A Flyvbjerg; K E Friend
Journal:  Endocr Rev       Date:  2000-06       Impact factor: 19.871

Review 4.  Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy.

Authors:  P Brodt; A Samani; R Navab
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

5.  The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients.

Authors:  Meinoshin Okumura; Mitsunori Ohta; Hisashi Tateyama; Katsuhiro Nakagawa; Akihide Matsumura; Hajime Maeda; Hiroto Tada; Tadaaki Eimoto; Hikaru Matsuda; Akira Masaoka
Journal:  Cancer       Date:  2002-02-01       Impact factor: 6.860

6.  Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies.

Authors:  Eric A Engels; Ruth M Pfeiffer
Journal:  Int J Cancer       Date:  2003-07-01       Impact factor: 7.396

7.  Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas.

Authors:  Masayoshi Inoue; Petr Starostik; Andreas Zettl; Philipp Ströbel; Stephan Schwarz; Francesco Scaravilli; Kristin Henry; Nick Willcox; Hans-Konrad Müller-Hermelink; Alexander Marx
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

8.  New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China.

Authors:  Gang Chen; Alexander Marx; Wen-Hu Chen; Jiang Yong; Bernhard Puppe; Philipp Stroebel; Hans Konrad Mueller-Hermelink
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

9.  Clinical spectrum of primary mediastinal tumors: a comparison of adult and pediatric populations at a single Japanese institution.

Authors:  Shin-ichi Takeda; Shinichiro Miyoshi; Akinori Akashi; Mitsunori Ohta; Masato Minami; Meinoshin Okumura; Akira Masaoka; Hikaru Matsuda
Journal:  J Surg Oncol       Date:  2003-05       Impact factor: 3.454

Review 10.  The insulin-like growth factor system and cancer.

Authors:  Derek LeRoith; Charles T Roberts
Journal:  Cancer Lett       Date:  2003-06-10       Impact factor: 8.679

View more
  14 in total

1.  NUT rearrangement is uncommon in human thymic epithelial tumors.

Authors:  Petrini Petrini; Christopher A French; Arun Rajan; Michael J Cameron; Elaine S Jaffe; Paolo A Zucali; Jianwu Xie; Yisong Wang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

2.  Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.

Authors:  Arun Rajan; Corey A Carter; Arlene Berman; Liang Cao; Ronan J Kelly; Anish Thomas; Sean Khozin; Ariel Lopez Chavez; Isabella Bergagnini; Barbara Scepura; Eva Szabo; Min-Jung Lee; Jane B Trepel; Sarah K Browne; Lindsey B Rosen; Yunkai Yu; Seth M Steinberg; Helen X Chen; Gregory J Riely; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2014-01-15       Impact factor: 41.316

3.  Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies.

Authors:  Mutsuko Omatsu; Toshiaki Kunimura; Tetsuya Mikogami; Shigeharu Hamatani; Akira Shiokawa; Atsuko Masunaga; Akihiko Kitami; Takashi Suzuki; Mitsutaka Kadokura; Toshio Morohoshi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-10-03

Review 4.  Thymic malignancies: from clinical management to targeted therapies.

Authors:  Ronan J Kelly; Iacopo Petrini; Arun Rajan; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

5.  Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.

Authors:  Fabio Conforti; Xu Zhang; Guanhua Rao; Tommaso De Pas; Yoko Yonemori; Jose Antonio Rodriguez; Justine N McCutcheon; Raneen Rahhal; Anna T Alberobello; Yisong Wang; Yu-Wen Zhang; Udayan Guha; Giuseppe Giaccone
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

6.  Reproducibility of the WHO classification of thymomas: practical implications.

Authors:  P A Zucali; L Di Tommaso; I Petrini; S Battista; H S Lee; M Merino; E Lorenzi; E Voulaz; F De Vincenzo; M Simonelli; M Roncalli; L Giordano; M Alloisio; A Santoro; G Giaccone
Journal:  Lung Cancer       Date:  2012-12-29       Impact factor: 5.705

Review 7.  Targeted therapy for advanced thymic tumors.

Authors:  Arun Rajan; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

8.  Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies.

Authors:  Giovannella Palmieri; Carlo Buonerba; Piera Federico; Luigi Formisano; Lucia Nappi; Giuseppe Di Lorenzo; Mirella Marino; Vincenzo Damiano
Journal:  World J Clin Oncol       Date:  2012-07-10

9.  Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.

Authors:  Iacopo Petrini; Yisong Wang; Paolo A Zucali; Hye Seung Lee; Trung Pham; Donna Voeller; Paul S Meltzer; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

10.  A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.

Authors:  Iacopo Petrini; Paul S Meltzer; In-Kyu Kim; Marco Lucchi; Kang-Seo Park; Gabriella Fontanini; James Gao; Paolo A Zucali; Fiorella Calabrese; Adolfo Favaretto; Federico Rea; Jaime Rodriguez-Canales; Robert L Walker; Marbin Pineda; Yuelin J Zhu; Christopher Lau; Keith J Killian; Sven Bilke; Donna Voeller; Sivanesan Dakshanamurthy; Yisong Wang; Giuseppe Giaccone
Journal:  Nat Genet       Date:  2014-06-29       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.